Where does Globe Biomedical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Globe Biomedical, Inc. ranks #47,109 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Globe Biomedical, Inc. hold?

Globe Biomedical, Inc. holds 5 US utility patents granted between 2023 and 2025, spanning 4 technology areas.

What is Globe Biomedical, Inc.'s Innovation Score?

Globe Biomedical, Inc. has an Innovation Score of 34.6 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Globe Biomedical, Inc. focus on?

Globe Biomedical, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 2 patents. Grants appear in 4 CPC subclasses total.

Is Globe Biomedical, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Globe Biomedical, Inc..

What does claim depth mean for Globe Biomedical, Inc.'s patents?

Globe Biomedical, Inc.'s patents average 13.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Globe Biomedical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Globe Biomedical, Inc.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Globe ranks #47,109 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#47,109
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.6/100): 13.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R47109 · US Corporation #47,109 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #47,109/49,997
PHOTO-FINISH Global Software…
CPC-NARROW A61B · 4 areas
INNOV-THIN 34.6/100
CLAIMS-RICH 13.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Global Software Innovation Pty Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Globe Biomedical · this assignee

35
3D Lighting… · lowest

7

What this shows Globe's Innovation Score is 34.6/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Globe's grants concentrate

Globe Biomedical, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 40% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, Globe sits between Global Software Innovation Pty Ltd and Gloucestershire Hospitals NHS Foundation Trust.

Globe's three-year grant acceleration

Globe Biomedical, Inc. shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Global Software I…

5
Global Sports & E…

5
Global Standard T…

5
Global Vapor Cont…

5
Glorious

5
Glory Global Solu…

5
Glorymakeup

5
Gloucestershire H…

5
Globe Biomedical ◀

5

What this shows Globe holds 5 patents at rank #47,200, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Globe

By rank, the assignees closest to #47,200 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Globe's primary technology class.

Globe's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Globe Biomedical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	1	20.0%
2024	1	20.0%
2025partial year	3	60.0%

Which technologies does Globe Biomedical, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 2

G02C - SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#47,109

of 49,997 tracked assignees

Innovation Score

34.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Globe Biomedical, Inc.'s patent record in context - here's where to go next.

Globe Biomedical, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 40% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #47,109 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Globe Biomedical, Inc. against Global Software Innovation Pty Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.